GO
Loading...

Pharmaceuticals

More

  • Why Pfizer will remain strong  Tuesday, 27 Jan 2015 | 6:45 PM ET

    Raghuram Selvaraju, Managing Director of Equity Research for Healthcare at MLV & Co, says there's lots of leverage the company can employ to sustain strong earnings growth.

  • Jan 27- Amgen Inc on Tuesday reported higher-than-expected fourth-quarter profit, driven by strong sales of its blockbuster rheumatoid arthritis drug Enbrel and a tax credit. Despite pressure on overseas sales from the strong dollar that has put a crimp in pharmaceutical company profits, Amgen reiterated the 2015 forecast it provided in October for...

  • NEW YORK, Jan 27- Pfizer Inc said on Tuesday it agreed to pay $400 million to avert a trial in a class action lawsuit accusing the pharmaceutical giant of misleading investors in connection with off-label marketing. Pfizer disclosed the agreement-in-principle as it released its fourth-quarter results. "This resolution reflects a desire by the company to...

  • Bristol-Myers quarterly profit beats forecasts Tuesday, 27 Jan 2015 | 9:22 AM ET
    Bristol-Myers Squibb R&D headquarters.

    Bristol-Myers Squibb reported higher-than-expected earnings, helped by strong sales of its hepatitis C drugs and its Eliquis blood clot preventer.

  • Jan 27- Bristol-Myers Squibb Co on Tuesday said profits could fall as much as 16 percent in 2015, a worse forecast than Wall Street had expected, as the stronger dollar takes a toll on U.S. drugmakers. Bristol-Myers, whose shares fell almost 2 percent in premarket trading, said it earned $13 million, or 1 cent per share, in the fourth quarter. Revenue fell 4 percent to...

  • Pfizer Inc.' s fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research and legal costs also reduced the bottom line. Pfizer revenues have been declining for several years amid patent expirations, which allow cheaper generic versions of its drugs to corner the market, while CEO Ian...

  • Bristol-Myers quarterly profit beats forecasts Tuesday, 27 Jan 2015 | 7:56 AM ET

    Jan 27- Bristol-Myers Squibb Co reported higher-than-expected quarterly earnings, helped by surprisingly strong sales of its hepatitis C drugs and its Eliquis blood clot preventer. The U.S. drugmaker on Tuesday said it earned $13 million, or 1 cent per share, in the fourth quarter. Revenue fell 4 percent to $4.26 billion, coming in above Wall Street expectations...

  • NEW YORK— Bristol-Myers Squibb Co. barely broke even in the fourth quarter, due to a whopping pension charge and slightly lower prescription drug sales, but the drugmaker easily beat Wall Street's muted profit expectations. Giovanni Caforio, 50, will take over running the company on May 5, the company said last week. The company took a $740 million charge for...

  • Jan 27- Pfizer Inc reported stronger-than-expected quarterly results as sales of vaccines and cancer drugs increased, but the company forecast 2015 earnings below Wall Street expectations, citing patent expirations and the stronger dollar. The largest U.S. drugmaker said on Tuesday that it earned $1.23 billion, or 19 cents per share, in the fourth quarter.

  • Procter& Gamble's second-quarter earnings sank 31 percent as the strong U.S. dollar cut into the performance of the world's largest consumer products maker. Health care products maker Johnson& Johnson and drugmaker Pfizer Inc. also recently reported a hit from foreign exchange rates. In the quarter that ended Dec. 31, P&G earned $2.37 billion, or 82 cents per...

  • Impact of a strong U.S. dollar  Tuesday, 27 Jan 2015 | 5:50 AM ET

    Cole Smead, portfolio manager at Smead Capital Management, discusses the strong U.S. dollar and how it will affect sectors like pharmaceuticals.

  • Swiss drug maker Novartis posts Q4 profit drop Tuesday, 27 Jan 2015 | 3:36 AM ET

    BERLIN— Swiss pharmaceutical giant Novartis AG says fourth quarter net income dropped 26 percent but the company still posted a healthy 2014 annual profit. The Basel, Switzerland- based company said Tuesday that fourth quarter net income came in at $1.49 billion, down from $2 billion in the same quarter the year before excluding its blood-transfusion...

  • *Core EPS $1.21 vs $1.18 forecast in Reuters poll. ZURICH, Jan 27- Swiss drugmaker Novartis forecast sales and profits to grow at a faster pace this year as recent drug successes and its portfolio overhaul help it weather the impact of generic competition. Novartis unveiled a transformative series of deals last year which will see it focus on a smaller number of...

  • WASHINGTON, Jan 26- A seller of green coffee bean supplements has agreed to stop deceptive advertising saying that the treatments help users lose weight, a claim that was made on "The Dr. The FTC charged that Lindsey Duncan, whose companies are Pure Health LLC and Genesis Today Inc, had claimed that an extract made of unroasted coffee beans would help people lose 17...

  • LONDON, Jan 26- Pfizer is to cut the price of its pneumococcal vaccine Prevenar 13 by 6 percent to $3.10 per dose in poor countries as part of a commitment to the GAVI global vaccines alliance, the U.S. drugmaker said on Monday. Pfizer's move comes as GAVI holds a major funding conference in Berlin at which it hopes to raise $7.5 billion from donors to pay for increased...

  • Jan 26- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug. Nexium raked in about $1.9 billion in global sales in the first half of 2014, according to AstraZeneca's latest earnings statement.

  • NEW YORK, Jan 26- A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease. But top oncology researchers are concerned about the two emerging technologies, citing...

  • Shares of Array BioPharma soared Friday after the drug developer said it will buy worldwide rights to a potential cancer treatment in late-stage clinical testing from Swiss pharmaceutical giant Novartis. The Boulder, Colorado, company said the deal is conditional on Novartis closing some acquisitions with British drugmaker GlaxoSmithKline PLC that it...

  • LONDON, Jan 23- The first batch of GlaxoSmithKline's experimental Ebola vaccine has been dispatched to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said. The World Health Organization said on Thursday the Ebola outbreak in West Africa, the worst in history, appears to be waning but cautioned against complacency.

  • How health care is changing: Kaiser Permanente CEO Friday, 23 Jan 2015 | 7:13 AM ET
    Bernard Tyson at the 2015 WEF in Davos, Switzerland.

    Health care utilization is not dropping, but shifting toward a great focus on outpatient care, Bernard Tyson told CNBC.